Retatrutide: The Triple-Hormone Weight Breakthrough | Health and Fitness News

Eli Lilly’s experimental drug retatrutide is blowing the weight loss and diabetes world away—showing up to 23% body weight loss and stellar blood sugar control in phase three trials. Unlike Ozempic or Mounjaro, it hits three hormone receptors (GLP-1, GIP, glucagon) for a triple-threat approach, delivered weekly via injection. It’s already impressing in trials for both type two diabetes and severe obesity with heart disease, even outperforming expectations in the diabetes group. But don’t ignore the downsides: diarrhea, nausea, and constipation plagued many, with over 10% discontinuing treatment. Still, with FDA approval potentially on the horizon by early 20...